Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II clinical trial of QR-1123 (IONIS-RHO-2.5Rx) in patients with P23H autosomal dominant retinitis pigmentosa (adRP)

Trial Profile

A Phase I/II clinical trial of QR-1123 (IONIS-RHO-2.5Rx) in patients with P23H autosomal dominant retinitis pigmentosa (adRP)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs QR-1123 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 29 Jan 2019 According to the ProQR Therapeutics, updates from the study announced in ProQR Vision 2023 strategy and will be presented at an R&D day event. Data expected in 2020.
    • 12 Nov 2018 New trial record
    • 29 Oct 2018 According to a ProQR Therapeutics media release, subject to submission and clearance of the IND application by the U.S. Food and Drug Administration (FDA), the company expects to initiate this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top